Pmv Pharmaceuticals, Inc
Clinical trials sponsored by Pmv Pharmaceuticals, Inc, explained in plain language.
A clinical-stage biotech developing precision oncology drugs targeting p53 mutations.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New cancer Drug's interaction with other meds under scrutiny in early trial
Knowledge-focused Recruiting nowThis early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal…
Phase: PHASE1 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC